JMP Securities Sees 80% Chance Of FDA Approval For Raptor's RP103 [View article]
If you had bought RPTP on the day this article was published, you could sell it for 25% higher, two months later. The stock is at the same level now as it was when it was published.
Navidea's Share Price Could Double This Year [View article]
Uri Landseman put his money where his mouth is. I think he really believe in this company.
As for the SPA - I can show you a list of companies (like PLX) that while holding SPA, they have been delayed by the FDA once or twice, or even rejected and the opposite.
Pharma And Biotechs With FDA Drug Approval Decisions In Q2 2012 [View article]
Regarding to Protalix, It's all about approving their blockbuster technology and less about their drug. Regarding to that, one should expect for a dramatic increase upon the approval. but if you insist, the treatment for the drug is very expansive - $250,000 a year, and Protalix and Pfizer are planning to sell it for much lower price duo to lower costs that this technology brings. Please do more research next time.
Protalix BioTherapeutics: Near-Term Catalysts With Big Upside Potential [View article]
What I meant to say is that you never wrote one good word on any article you comment (not specific on that one).. I dont think that someone appoint you as a state comptroller. In this case, PLX is very positive in the eyes of many analysts and none of them sees your issues as significant.
Maxim Group Sees 350% Upside In Shares Of Omeros Corporation [View article]
Vivus Still Needs The Help Of A Big Pharma Partner, Say Cowen's Analysts [View article]
JMP Securities Sees 80% Chance Of FDA Approval For Raptor's RP103 [View article]
Cystagon is currently priced at about $9,000 per year.
I think the drug will be approved, but , I'm not a buyer at the current price.
Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid [View article]
Maxim Group Highlights 3 Stem Cell Stocks To Consider And 1 To Avoid [View article]
JMP Securities Sees 80% Chance Of FDA Approval For Raptor's RP103 [View article]
WBB Securities Recommends Alexza Pharmaceuticals As A Strong Buy [View article]
WBB Securities Recommends Alexza Pharmaceuticals As A Strong Buy [View article]
Navidea's Share Price Could Double This Year [View article]
However, I agree, beside that NAVB got a strong pipeline.
Navidea's Share Price Could Double This Year [View article]
As for the SPA - I can show you a list of companies (like PLX) that while holding SPA, they have been delayed by the FDA once or twice, or even rejected and the opposite.
Vivus: Another Potentially Safe Short Play On Likely Drug Rejection [View article]
People should at least give you credibility on that and listen.
If VVUS will not win the FDA approval - you will be a legend!
Pharma And Biotechs With FDA Drug Approval Decisions In Q2 2012 [View article]
Protalix BioTherapeutics: Near-Term Catalysts With Big Upside Potential [View article]
Protalix BioTherapeutics: Near-Term Catalysts With Big Upside Potential [View article]
4 Biotech Sleepers With Over 100% Upside [View article]
This is the presentaion. where exactly do you see 10 million in yearly revenue projection?
The only number that was mention regarding to CPI300 was:
"$150 million market"